Indication
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Loading your page…
Loading your page…
Epilepsy
Marketing Authorisation Holder: UCB Pharma SA
EMA Authorisation: 13/01/2016
INN: brivaracetam
AI Drug & Interaction Analysis
Free account required
Ask Osler about Briviact (in Italy: Nubriveo): drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.